<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="569">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820127</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0555</org_study_id>
    <nct_id>NCT04820127</nct_id>
  </id_info>
  <brief_title>Personalized Management of Psycho-behavioral Symptoms in Alzheimer's Disease: Impact on Health Resources Use</brief_title>
  <acronym>PERSON-AL</acronym>
  <official_title>Personalized Management of Psycho-behavioral Symptoms in Alzheimer's Disease and Related Disorders: Impact on Health Resources Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project propose to study the effectiveness of a personalized care management of&#xD;
      psycho-behavioral symptoms based on an evidence-based standardized assessment to identify and&#xD;
      understand the underlying causes of psycho-behavioral symptoms followed by a personalized&#xD;
      intervention based on targeted and prioritized actions. This personalized intervention is&#xD;
      proposed both to Alzheimer disease (AD) patients living at home with agitation-type&#xD;
      psycho-behavioral symptoms, and also to their caregivers with the support and coordination of&#xD;
      a nurse working in collaboration with the specialist physician and the General Practitioner&#xD;
      (GP). News technologies are used to enhance the follow-up, based on telehealth, and caregiver&#xD;
      training.&#xD;
&#xD;
      The project hypothesize that, for a vulnerable population at risk (AD patient with agitation&#xD;
      and their caregivers) living at home, a personalized intervention, carried out and&#xD;
      coordinated by a nurse in close collaboration with the specialist and GP, would reduce&#xD;
      hospitalizations and have a positive effect on the disease evolution and caregiver distress.&#xD;
      Also this personalized intervention could reduce the cost of care, in particular by reducing&#xD;
      the costs associated with hospitalizations and informal help.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PERSON-AL is a multicentric, interventional, open-label, randomized, parallel-group,&#xD;
      stratified by centre, study comparing two arms: usual care versus intervention (personalized&#xD;
      care preceded by a standardized assessment)&#xD;
&#xD;
      Principal Objective : To evaluate the impact of a personalized intervention for the&#xD;
      management of agitation due to psycho-behavioral symptoms on the use of scheduled and&#xD;
      unscheduled hospitalizations at 18 months in patients with AD and related disorders.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      A- To evaluate the impact of a personalized intervention at 18 months on:&#xD;
&#xD;
      For the patient:&#xD;
&#xD;
        1. Unscheduled hospitalizations,&#xD;
&#xD;
        2. Severity of agitation symptoms,&#xD;
&#xD;
        3. The frequency and severity of emerging psycho-behavioral symptoms, other than agitation,&#xD;
&#xD;
        4. Prescription of psychotropic drugs,&#xD;
&#xD;
        5. Quality of life.&#xD;
&#xD;
           For the caregiver:&#xD;
&#xD;
        6. Distress related to psycho-behavioral symptoms,&#xD;
&#xD;
        7. All causes hospitalizations,&#xD;
&#xD;
        8. Quality of life.&#xD;
&#xD;
      B- Evaluate the medico-economic impact of this personalized intervention, and in particular:&#xD;
&#xD;
        1. Its efficiency compared to usual management by means of cost-effectiveness and&#xD;
           cost-utility analyses, from the community perspective and over a time horizon of 18&#xD;
           months,&#xD;
&#xD;
        2. The actual cost of patient's standardized assessment and personalized management&#xD;
&#xD;
        3. The use of care and associated costs for the caregiver and the efficiency of caregiver&#xD;
           targeted intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient's number of hospitalization at 18 months</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>number of all causes hospitalization, either scheduled or unscheduled, including emergency department visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient's unscheduled hospitalization</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>all causes hospitalization, unscheduled, including emergency department visits</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient agitation symptoms severity</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>assessed by Neuropsychiatric Inventory Clinician (NPI-C) scale based on the International Psychogeriatrics Association (IPA) (NPI-C-IPA) and Cohen-Mansfield Agitation Inventory (CMAI).</description>
  </other_outcome>
  <other_outcome>
    <measure>severity and frequency of others emergent psycho-behavioral symptoms</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>assessed by the NPI scale&#xD;
Frequency (0-4) Severity (0-3): Caregiver Distress (0-5):</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of psychotropic drug prescription for the patient</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>prescription checked at each visit</description>
  </other_outcome>
  <other_outcome>
    <measure>patient's quality of life</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>assessed by the Euro Quality of life (EQ-5D-5L) scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's psycho-behavioral symptoms distress on the caregiver</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>&quot;distress&quot; score of the Neuropsychiatric Inventory-Clinician rating scale-IPA scale&#xD;
Frequency (0-4) Severity (0-3): Caregiver Distress (0-5):</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver's hospitalizations</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>all causes of hospitalization, either scheduled or unscheduled, including emergency department visits</description>
  </other_outcome>
  <other_outcome>
    <measure>caregiver's quality of life</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>assessed by the Euro Qol (EQ-5D-5L) scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost/efficiency ratio and cost /utility differential from the community perspective</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>Cost/efficiency ratio and cost /utility differential from the community perspective</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison between Standardized evaluation and personalized care program real cost</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>micro-costing approach of health costs</description>
  </other_outcome>
  <other_outcome>
    <measure>quantity and cost health system resources used by the patient</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>health system resources used by the patient quantity and cost in comparison with efficiency and cost from the community perspective.</description>
  </other_outcome>
  <other_outcome>
    <measure>efficiency and cost from the community perspective.</measure>
    <time_frame>From the inclusion until End of Study, 18 months</time_frame>
    <description>health system resources used by the patient quantity and cost in comparison with efficiency and cost from the community perspective.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">668</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Control (usual care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will benefit from the usual care with a half-yearly visit by the specialist physician (geriatrician, neurologist or psychiatrist) according to AD French national management guidelines (HAS 2011 and HAS 2018).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention (personalized care program)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the intervention group will benefit from personalized care preceded by a standardized assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>personalized care preceded by a standardized assessment</intervention_name>
    <description>personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;&#xD;
PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);&#xD;
specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;</description>
    <arm_group_label>Intervention (personalized care program)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For the patient :&#xD;
&#xD;
          -  Diagnosed with major neuro-cognitive disorders (DSM V) at all severity stages.&#xD;
&#xD;
          -  Leaving at home&#xD;
&#xD;
          -  Assisted by a caregiver, from patient's family or personal environment, assuming most&#xD;
             of patient care (spending at least 6 hours per week with the patient)&#xD;
&#xD;
          -  caregiver available to come with the patient to study visits as planned per protocol&#xD;
&#xD;
          -  existing agitation since at least one month (according to International&#xD;
             Psychogeriatric Association (IPA) criteria)&#xD;
&#xD;
          -  agitation severity ≥ 2 , based on Clinician Global Impression of Severity (CGI-S) (at&#xD;
             least mild severity)&#xD;
&#xD;
          -  the patient, his/her family member/trusted person , or his /her legal responsible has&#xD;
             provided written informed consent to participate in the study&#xD;
&#xD;
          -  referring physician's oral approval obtained for patient participation in the study&#xD;
&#xD;
          -  Affiliated to French Healthcare System&#xD;
&#xD;
        For the caregiver:&#xD;
&#xD;
          -  Has provided his/her written informed consent to participate in the study&#xD;
&#xD;
          -  Ability to understand and speak French properly, ability to complete the&#xD;
             questionnaires and assess the patient.&#xD;
&#xD;
          -  Affiliated to French Healthcare System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For the patient:&#xD;
&#xD;
          -  Agitation symptoms attributable either to other concomitant prescriptions, or to other&#xD;
             psychiatric or evolving somatic diseases.&#xD;
&#xD;
          -  Patient living in a residential care facility or having an institutionalization&#xD;
             project within 6 months&#xD;
&#xD;
          -  Patient with clinically significant or unstable disease that could affect he/her&#xD;
             ability to come for the study visit or complete the evaluations planned as per&#xD;
             protocol&#xD;
&#xD;
          -  Concomitant participation to any other interventional research study&#xD;
&#xD;
          -  Patient under legal protection.&#xD;
&#xD;
        For the caregiver:&#xD;
&#xD;
          -  Caregiver under legal protection.&#xD;
&#xD;
          -  Limited internet access or caregiver feeling unable to use it&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria SOTO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Toulouse - Gerontopole</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARIA SOTO, MD</last_name>
    <phone>5 61 77 70 49</phone>
    <phone_ext>+33</phone_ext>
    <email>soto-martin.me@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie LESTIME</last_name>
    <phone>5 61 77 84 16</phone>
    <phone_ext>+33</phone_ext>
    <email>lestime.e@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Albi</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carine CHIFFRE, MD</last_name>
      <phone>05 63 47 48 56</phone>
      <phone_ext>+33</phone_ext>
      <email>carine.chiffre@ch-albi.rss.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Cahors</name>
      <address>
        <city>Cahors</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David DOMBROWSKI, MD</last_name>
      <phone>05 65 20 54 83</phone>
      <phone_ext>+33</phone_ext>
      <email>david.DOMBROWSKI@ch-cahors.fr</email>
    </contact>
    <investigator>
      <last_name>David DOMBROWSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inga COUFFIGNAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carcassonne Hospital</name>
      <address>
        <city>Carcassonne</city>
        <zip>11000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédérique NATHAN-BONNET, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Frédérique NATHAN-BONNET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna BAKANOVA-KOUMOUVI, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Castres Mazamet</name>
      <address>
        <city>Castres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Noëlle Cufi, MD</last_name>
      <phone>05 63 71 62 91</phone>
      <phone_ext>+33</phone_ext>
      <email>mn-cufi@chic-cm.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Noëlle CUFI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine LEFORT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Lannemezan</name>
      <address>
        <city>Lannemezan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre SALLES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre SALLES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge BORDES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Lavaur</name>
      <address>
        <city>Lavaur</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françoise DESCLAUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Françoise DESCLAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline GUILLEMAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limoges university hospital</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Achille TCHALLA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Achille TCHALLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre KROLAK-SALMON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre KROLAK-SALMON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien VERNAUDON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis LEPETIT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie Roustan, MD</last_name>
      <phone>05.63.92.81.31</phone>
      <phone_ext>+33</phone_ext>
      <email>a.roustan@ch-montauban.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narbonne Hospital</name>
      <address>
        <city>Narbonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas BOUDET, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas BOUDET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perpignan Hospital</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geneviève BARNIER-FIGUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Geneviève BARNIER-FIGUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Val d'Ariège</name>
      <address>
        <city>Saint Girons</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lawrence Bories, MD</last_name>
      <phone>05 61 03 33 91</phone>
      <email>l.bories@chi-val-ariege.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital (CHU de Toulouse)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria SOTO, MD, Ph D</last_name>
      <email>soto-martin.me@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno VELLAS, MD, Ph D, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Jean OUSSET, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien DELRIEU, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adélaïde DE MAULEON, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion BAZIARD, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille CRANSAC, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry VOISIN, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Bahia ABDELJALIL, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal SAIDLITZ, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise LALA, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie SASTRE, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène VILLARS, MD, Ph D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Toulouse - Neurology department</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémy PARIENTE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jérémy PARIENTE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie RAFIQ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie BENAITEAU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jasmine CARLIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille TISSERAND, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bigorre</name>
      <address>
        <city>Vic en Bigorre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yannick Gasnier, MD</last_name>
      <phone>05 62 54 70 15</phone>
      <phone_ext>+33</phone_ext>
      <email>ygasnier@ch-tarbes-vic.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

